EP0954313A4 - Method for treating tumors having high ldl requirements employing mtp inhibitors - Google Patents

Method for treating tumors having high ldl requirements employing mtp inhibitors

Info

Publication number: EP0954313A4
Authority: EP; European Patent Office
Prior art keywords: treating tumors; high ldl; mtp inhibitors; employing; requirements
Prior art date: 1996-07-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP97932594A

Other languages

German (de)

French (fr)

Other versions

EP0954313A1 (en

Inventor

Raymond A Firestone

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Bristol Myers Squibb Co

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-07-24

Filing date

1997-07-14

Publication date

2003-07-02

1997-07-14 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

1999-11-10 Publication of EP0954313A1 publication Critical patent/EP0954313A1/en

2003-07-02 Publication of EP0954313A4 publication Critical patent/EP0954313A4/en

Status Withdrawn legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Obesity (AREA)
Communicable Diseases (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

EP97932594A 1996-07-24 1997-07-14 Method for treating tumors having high ldl requirements employing mtp inhibitors Withdrawn EP0954313A4 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US2286396P	1996-07-24	1996-07-24
US22863P		1996-07-24
PCT/US1997/012158 WO1998003174A1 (en)	1996-07-24	1997-07-14	Method for treating tumors having high ldl requirements employing mtp inhibitors

Publications (2)

Publication Number	Publication Date
EP0954313A1 EP0954313A1 (en)	1999-11-10
EP0954313A4 true EP0954313A4 (en)	2003-07-02

Family

ID=21811838

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP97932594A Withdrawn EP0954313A4 (en)	1996-07-24	1997-07-14	Method for treating tumors having high ldl requirements employing mtp inhibitors

Country Status (4)

Country	Link
EP (1)	EP0954313A4 (en)
JP (1)	JP2002513379A (en)
CA (1)	CA2261162A1 (en)
WO (1)	WO1998003174A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6288234B1 (en)	1998-06-08	2001-09-11	Advanced Medicine, Inc.	Multibinding inhibitors of microsomal triglyceride transferase protein
DK1725234T4 (en)	2004-03-05	2016-05-09	Univ Pennsylvania	METHODS OF TREATING DISEASES OR DISEASES CONNECTED WITH HYPERLIPIDEMIA AND HYPERCOLESTEROLYMIA WITH MINIMIZATION OF SIDE EFFECTS
WO2005094864A2 (en) *	2004-03-30	2005-10-13	Max-Planck Gesellschaft zur Förderung der Wissenschaften e.V.	Treatment of hedgehog- and wnt-secreting tumors with inhibitors of lipoprotein particle biogenesis
US20230346762A1 (en) *	2020-02-21	2023-11-02	Korea Advanced Institute Of Science And Technology	Pharmaceutical composition for preventing or treating cancer, containing mtor-signaling inhibitor as active ingredient

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0584446A2 (en) *	1992-03-06	1994-03-02	E.R. SQUIBB & SONS, INC.	Microsomal triglyceride transfer protein

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5595872A (en) *	1992-03-06	1997-01-21	Bristol-Myers Squibb Company	Nucleic acids encoding microsomal trigyceride transfer protein

1997
- 1997-07-14 JP JP50701298A patent/JP2002513379A/en active Pending
- 1997-07-14 WO PCT/US1997/012158 patent/WO1998003174A1/en not_active Application Discontinuation
- 1997-07-14 EP EP97932594A patent/EP0954313A4/en not_active Withdrawn
- 1997-07-14 CA CA002261162A patent/CA2261162A1/en not_active Abandoned

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0584446A2 (en) *	1992-03-06	1994-03-02	E.R. SQUIBB & SONS, INC.	Microsomal triglyceride transfer protein

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MALTESE, W. A.; DEFENDINI, R.; GREEN, R. A.; SHERIDAN, K. M.; DONLEY, D. K.: "Suppression of Murine Neuroblastoma Growth In Vivo by Mevinolin, a Competitive Inhibitor of 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase", JOURNAL OF CLINICAL INVESTIGATION, vol. 76, - 1 November 1985 (1985-11-01), pages 1748 - 1754, XP009010279 *
MIKULSKI S M ET AL: "SYNERGISM BETWEEN A NOVEL AMPHIBIAN OOCYTE RIBONUCLEASE AND LOVASTATIN IN INDUCING CYTOSTATIC AND CYTOTOXIC EFFECTS IN HUMAN LUNG AND PANCREATIC CARCINOMA CELL LINES", BRITISH JOURNAL OF CANCER, LONDON, GB, vol. 66, no. 2, August 1992 (1992-08-01), pages 304 - 310, XP000857575, ISSN: 0007-0920 *
See also references of WO9803174A1 *
THIBAULT, A; SAMID, D; TOMPKINS, A C; FIGG, W J; COOPER, M R; HOHL R J; TREPEL, J; LIANG, B; PATRONAS, N; VENZON, D J; REED, E: "Phase I Study of Lovastatin, an Inhibitor of the Mevalonate Pathway, in Patients with Cancer", CLINICAL CANCER RESEARCH, vol. 2, pages 483 - 491, XP001147434 *

Also Published As

Publication number	Publication date
CA2261162A1 (en)	1998-01-29
EP0954313A1 (en)	1999-11-10
WO1998003174A1 (en)	1998-01-29
JP2002513379A (en)	2002-05-08
AU3600897A (en)	1998-02-10
AU712303B2 (en)	1999-11-04

Publication	Publication Date	Title
AU1527897A (en)	1997-08-20	Method for treating the prostate
PL330782A1 (en)	1999-06-07	Method of treating carcinoma using the inhibitors of naaladase
AU3813397A (en)	1998-03-06	Apparatus for treating chondromalicia
AU3829895A (en)	1996-05-06	Methods for treating resistant tumors
IL126759A0 (en)	1999-08-17	Method for treating inflammation
AU2584597A (en)	1997-10-17	Method for treating migraine pain
AU4672597A (en)	1998-05-15	Method for treating urinary reflux
AU6760298A (en)	1998-10-30	Method for treating hypertension
EG23945A (en)	2008-01-22	Method for treating COPD
EP0954313A4 (en)	2003-07-02	Method for treating tumors having high ldl requirements employing mtp inhibitors
AU6688798A (en)	1998-09-22	Method for treating lumber
AU7602896A (en)	1997-05-29	Methods for treating resistant tumors
AU9615198A (en)	1999-05-10	Magnetic apparatus for treating fluid fuels
IL126162A0 (en)	1999-05-09	Method for treating bipolar disorder
HUP9903779A3 (en)	2002-01-28	Method for treating amyotrophic lateral sclerosis
AU5369498A (en)	1998-06-22	Compounds and methods for treating cancer
AU3896597A (en)	1998-02-25	Method for treating substance abuse
ZA971899B (en)	1998-09-07	Method for treating insomnia
AU2443599A (en)	2000-02-21	Method for treating neoplasms
GB9517701D0 (en)	1995-11-01	Method for treating hyperlipidemia
EP1043994A4 (en)	2002-09-11	Method for treating multiple sclerosis
AU2198997A (en)	1997-10-01	Method for treating insomnia
AU7104898A (en)	1998-11-11	Synergistic method for treating cancer
IL119272A0 (en)	1996-12-05	Method for treating acne
HK1007887A (en)	1999-04-30	Method for treating tumors

Legal Events

Date	Code	Title	Description
1999-09-24	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
1999-11-10	17P	Request for examination filed	Effective date: 19990119
1999-11-10	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
2003-07-02	A4	Supplementary search report drawn up and despatched	Effective date: 20030519
2003-07-02	RIC1	Information provided on ipc code assigned before grant	Ipc: 7A 61P 31/00 B Ipc: 7A 61P 3/06 B Ipc: 7A 61K 31/445 A
2003-11-05	17Q	First examination report despatched	Effective date: 20030922
2004-06-18	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2004-08-04	18D	Application deemed to be withdrawn	Effective date: 20040203